ReviewClinical diabetes and endocrinology2016
Update on medical treatment for Cushing's disease.
Review in Clinical diabetes and endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- The Potential Role of SGLT2 Inhibitors in Cushing's Disease.Diabetes, obesity & metabolism · 2026Review
- Etomidate in severe hypercortisolism: early cortisol kinetics and clinical outcomes in a real-world cohort.Pituitary · 2026Article
- Mifepristone alone and in combination with scAAV9-SMN1 gene therapy improves disease phenotypes in SmnScientific reports · 2025Article
- Molecular and Genetics Perspectives on Primary Adrenocortical Hyperfunction Disorders.International journal of molecular sciences · 2024Review
- Cushing's disease presenting with recurrent abscesses followed by post-remission hyperthyroidism.Endocrinology, diabetes & metabolism case reports · 2024Article
- Classification of Cushing's syndrome PKAc mutants based upon their ability to bind PKI.The Biochemical journal · 2023Article
- The bromodomain inhibitor JQ1+ reduces calcium-sensing receptor activity in pituitary cell lines.Journal of molecular endocrinology · 2021Article
- Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.Frontiers in endocrinology · 2021Review
- The selective glucocorticoid receptor antagonist CORT125281 has tissue-specific activity.The Journal of endocrinology · 2020Article
- Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells.Endocrine-related cancer · 2020Article
- Driver mutations in USP8 wild-type Cushing's disease.Neuro-oncology · 2019Article
- Review
- Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies.European endocrinology · 2019Review
- Canagliflozin improves obesity and insulin resistance in a diabetic patient with Cushings disease undergoing postoperative steroid therapy: A case report.Biomedical reports · 2018Article
- New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.Frontiers in endocrinology · 2018Review
- Recent Progress in the Medical Therapy of Pituitary Tumors.Endocrinology and metabolism (Seoul, Korea) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cushing's disease (CD) is the most common cause of endogenous Cushing's syndrome (CS). The goal of treatment is to rapidly control cortisol excess and achieve long-term remission, to reverse the clinical features and reduce long-term complications associated with increased mortality. While pituitary surgery remains first line therapy, pituitary radiotherapy and bilateral adrenalectomy have traditionally been seen as second-line therapies for persistent hypercortisolism. Medical therapy is now recognized to play a key role in the control of cortisol excess. In this review, all currently available medical therapies are summarized, and novel medical therapies in phase 3 clinical trials, such as osilodrostat and levoketoconazole are discussed, with an emphasis on indications, efficacy and safety. Emerging data suggests increased efficacy and better tolerability with these novel therapies and combination treatment strategies, and potentially increases the therapeutic options for treatment of CD. New insights into the pathophysiology of CD are highlighted, along with potential therapeutic applications. Future treatments on the horizon such as R-roscovitine, retinoic acid, epidermal growth factor receptor inhibitors and somatostatin-dopamine chimeric compounds are also described, with a focus on potential clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.